Replies to post #5233 on BioSante Pharmaceuticals, Inc. (BPAX)

[keekee]

John. Bio-T-Gel is $17 billion market in 3 years

"Take is Elestrin for instance. It's a treatment for menopause symptoms - a market estimated to be worth anywhere from $2 billion to $8 billion per year. The wide variances in its size underscore the idea that many women don't treat it, but would if the right product was available. Elestrin is already FDA-approved.

BioSante is also developing Bio T-Gel for male hypogonadism, and The Pill-Plus contraceptive. The latter will be a $17 billion market within three years."

Link is there for a read, but the momo hasn't even started. For instance, the pill somx was doing was only estimated at $3 billion


Link: http://www.smallcapnetwork.com/Before-Discarding-BioSante-Pharmaceuticals-BPAX-Forever/s/via/1789/article/view/p/mid/3/id/80/

[Just the facts maam]

The market for Bio-t-gel was estimated at $1.2 billion in 2010

Market